Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ blood
COVID-19
/ immunology
Female
Follow-Up Studies
Humans
Immunoglobulin G
/ blood
Male
Middle Aged
Prospective Studies
Protein Domains
/ immunology
Renal Dialysis
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ immunology
Young Adult
Journal
Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
pubmed:
18
5
2021
medline:
1
9
2021
entrez:
17
5
2021
Statut:
ppublish
Résumé
Assessing the evolution of SARS-CoV-2 immune response among patients receiving dialysis can define its durability in a highly clinically relevant context because patients receiving dialysis share the characteristics of persons most susceptible to SARS-CoV-2 infection. To evaluate the persistence of SARS-CoV-2 receptor-binding domain (RBD) IgG in seroprevalent patients receiving dialysis. Prospective. Nationwide sample from dialysis facilities. 2215 patients receiving dialysis who had evidence of SARS-CoV-2 infection as of July 2020. Remainder plasma from routine monthly laboratories was used to measure semiquantitative RBD IgG index value over 6 months. A total of 2063 (93%) seroprevalent patients reached an assay detectable response (IgG index value ≥1). Most ( Lack of data on symptoms or reverse transcriptase polymerase chain reaction diagnosis, cohort of persons who survived infection, and use of a semiquantitative assay. Despite impaired immunity, most seropositive patients receiving dialysis maintained RBD antibody levels over 6 months. A slow and continual decline in median antibody levels over time was seen, but no indication that subgroups with impaired immunity had a shorter-lived humoral response was found. Ascend Clinical Laboratories.
Sections du résumé
BACKGROUND
Assessing the evolution of SARS-CoV-2 immune response among patients receiving dialysis can define its durability in a highly clinically relevant context because patients receiving dialysis share the characteristics of persons most susceptible to SARS-CoV-2 infection.
OBJECTIVE
To evaluate the persistence of SARS-CoV-2 receptor-binding domain (RBD) IgG in seroprevalent patients receiving dialysis.
DESIGN
Prospective.
SETTING
Nationwide sample from dialysis facilities.
PATIENTS
2215 patients receiving dialysis who had evidence of SARS-CoV-2 infection as of July 2020.
MEASUREMENTS
Remainder plasma from routine monthly laboratories was used to measure semiquantitative RBD IgG index value over 6 months.
RESULTS
A total of 2063 (93%) seroprevalent patients reached an assay detectable response (IgG index value ≥1). Most (
LIMITATION
Lack of data on symptoms or reverse transcriptase polymerase chain reaction diagnosis, cohort of persons who survived infection, and use of a semiquantitative assay.
CONCLUSION
Despite impaired immunity, most seropositive patients receiving dialysis maintained RBD antibody levels over 6 months. A slow and continual decline in median antibody levels over time was seen, but no indication that subgroups with impaired immunity had a shorter-lived humoral response was found.
PRIMARY FUNDING SOURCE
Ascend Clinical Laboratories.
Identifiants
pubmed: 34000201
doi: 10.7326/M21-0256
pmc: PMC8252842
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1073-1080Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK127138
Pays : United States